Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Bioatla Inc (BCAB)

Bioatla Inc (BCAB)
0.3250 x 5 0.3803 x 10
Pre-market by (Cboe BZX)
0.3560 +0.0010 (+0.28%) 03/19/25 [NASDAQ]
0.3250 x 5 0.3803 x 10
Pre-market 0.3560 unch (unch) 16:00 ET
Quote Overview for Wed, Mar 19th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.3500
Day High
0.3799
Open 0.3541
Previous Close 0.3550 0.3550
Volume 393,000 393,000
Avg Vol 811,690 811,690
Stochastic %K 83.16% 83.16%
Weighted Alpha -79.46 -79.46
5-Day Change +0.0209 (+6.24%) +0.0209 (+6.24%)
52-Week Range 0.2400 - 4.0200 0.2400 - 4.0200
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,211
  • Shares Outstanding, K 48,346
  • Annual Sales, $ 0 K
  • Annual Income, $ -123,460 K
  • EBIT $ -86 M
  • EBITDA $ -85 M
  • 60-Month Beta 1.19
  • Price/Sales 1.56
  • Price/Cash Flow N/A
  • Price/Book 0.76
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.70
  • Most Recent Earnings $-0.22 on 11/07/24
  • Next Earnings Date 03/27/25 [AMC]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 294.92% ( -62.20%)
  • Historical Volatility 105.01%
  • IV Percentile 77%
  • IV Rank 22.93%
  • IV High 1,145.12% on 02/19/25
  • IV Low 41.99% on 01/14/25
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 3,934
  • Open Int (30-Day) 3,831

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.33
  • Number of Estimates 1
  • High Estimate -0.33
  • Low Estimate -0.33
  • Prior Year -0.56
  • Growth Rate Est. (year over year) +41.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2400 +48.33%
on 03/04/25
Period Open: 0.4685
0.4685 -24.01%
on 02/20/25
-0.1125 (-24.01%)
since 02/19/25
3-Month
0.2400 +48.33%
on 03/04/25
Period Open: 1.1900
1.0800 -67.04%
on 12/20/24
-0.8340 (-70.08%)
since 12/19/24
52-Week
0.2400 +48.33%
on 03/04/25
Period Open: 2.4600
4.0200 -91.14%
on 04/04/24
-2.1040 (-85.53%)
since 03/19/24

Most Recent Stories

More News
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

BCAB : 0.3560 (+0.28%)
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

BCAB : 0.3560 (+0.28%)
BioAtla Reports Improved Survival Outcomes in NSCLC Patients with Mutated KRAS Treated with Mecbotamab Vedotin

Mec-V shows improved one-year survival in mKRAS NSCLC patients compared to wtKRAS, supporting further clinical trials.Quiver AI SummaryBioAtla, Inc. reported promising results for its treatment, Mecbotamab...

BCAB : 0.3560 (+0.28%)
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

BCAB : 0.3560 (+0.28%)
BioAtla, Inc. to Present Research on Mecbotamab Vedotin at IASLC 2024 Meeting

BioAtla will present research on Mecbotamab Vedotin at the IASLC meeting December 14, 2024, in Washington, DC.Quiver AI SummaryBioAtla, Inc., a clinical-stage biotechnology company specializing in Conditionally...

BCAB : 0.3560 (+0.28%)
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

BCAB : 0.3560 (+0.28%)
Michael Burry Cautiously Ups Alibaba, JD.com, Baidu Bets With Offsetting Hedges: Retail Doesn’t Share Big Short Investor’s Optimism

Burry is known for accurately predicting the 2007 subprime mortgage crisis that later morphed into the global financial crisis.

BABA : 143.20 (+0.32%)
ACIC : 12.05 (-0.74%)
MCHI : 58.31 (-0.09%)
BIDU : 98.24 (-4.17%)
REAL : 6.17 (+8.25%)
HPP : 2.94 (-1.01%)
JD : 44.83 (-0.20%)
BCAB : 0.3560 (+0.28%)
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

BCAB : 0.3560 (+0.28%)
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024

BCAB : 0.3560 (+0.28%)
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

BCAB : 0.3560 (+0.28%)

Business Summary

BioAtla Inc. is a clinical-stage biopharmaceutical company. It engages in developing a novel class of antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 0.4038
2nd Resistance Point 0.3919
1st Resistance Point 0.3739
Last Price 0.3560
1st Support Level 0.3440
2nd Support Level 0.3321
3rd Support Level 0.3141

See More

52-Week High 4.0200
Fibonacci 61.8% 2.5760
Fibonacci 50% 2.1300
Fibonacci 38.2% 1.6840
Last Price 0.3560
52-Week Low 0.2400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals